Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
22 nov. 2022 09h25 HE
|
Novartis Pharma AG
First data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and...
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
07 nov. 2022 16h24 HE
|
Novartis Pharma AG
Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol...
Novartis maintient sa dynamique de croissance et confirme les prévisions de l’exercice 2022 pour le Groupe
25 oct. 2022 01h00 HE
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T3 en hausse de +4% tcc1 (-4% USD) Innovative Medicines (IM) : hausse du chiffre d’affaires de +4% tcc (-3% USD), soutenue par...
Novartis setzt die Wachstumsdynamik fort und bestätigt die Konzernprognose für das Geschäftsjahr 2022
25 oct. 2022 01h00 HE
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im dritten Quartal um +4% kWk1 (–4% USD): Innovative Medicines (IM) steigerte den Umsatz um +4% kWk (–3% USD), getragen von den wichtigsten...
Novartis maintains growth momentum and confirms FY’22 Group guidance
25 oct. 2022 01h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven by key growth brands including: Entresto (+31% cc),...
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study
24 oct. 2022 01h15 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients...
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
14 oct. 2022 07h04 HE
|
Novartis Pharma AG
Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and...
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
10 sept. 2022 02h30 HE
|
Novartis Pharma AG
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and...
Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
09 sept. 2022 01h15 HE
|
Novartis Pharma AG
New large pooled exploratory analysis from MONALEESA-2, -3 and -7 reinforces unparalleled overall survival (OS) benefit of Kisqali plus ET compared to ET alone, in HR+/HER2- aBC patients with...
Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
02 sept. 2022 01h15 HE
|
Novartis Pharma AG
Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of...